首页> 外文期刊>Clinical Interventions in Aging >Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease
【24h】

Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease

机译:阿托伐他汀减弱了由淀粉样蛋白β1-42诱导的阿尔茨海默病大鼠模型海马中IL-1β,IL-6和TNF-α的产生

获取原文
           

摘要

Background and aim: Amyloid-beta (Aβ) peptide is reported to initiate flexible inflammation in the hippocampus of the human brain in Alzheimer’s disease (AD). The present study aimed to investigate the possible effects of atorvastatin on the production of inflammation cytokines in the hippocampus and the potential impacts on behavioral ability, in an AD model.Methods: We firstly established AD rat models using intracerebroventricular injection of Aβ1-42. A Morris water maze was also performed to determine the spatial learning and memory ability in the AD models. Intracellular staining of interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha was determined using immunohistochemical staining at 6 hours and day 7 after the injection of Aβ.Results: The escape latency of the atorvastatin-treated AD group (5 mg/kg/d) was significantly shorter than that of AD group on day 3 (41 ± 1.05 seconds versus 47 ± 1.05 seconds, P < 0.01) and day 4 (34 ± 1.25 seconds versus 43 ± 1.01 seconds, P < 0.01) after the beginning of the training. Furthermore, the atorvastatin-treated AD group displayed a significant higher mean number of annulus crossings than did the AD group (2.9 ± 0.5 versus 2.4 ± 0.9, P < 0.05). Fewer injured nerve cells and proliferated glial cells were also demonstrated in the atorvastatin-treated AD group than in the AD group. Of great importance, we demonstrated that IL-1β, IL-6, and tumor necrosis factor alpha were significantly decreased in the atorvastatin-treated AD group than that in the AD group.Conclusion: Atorvastatin might attenuate the damage of nerve cells and improve learning and memory ability by inhibiting inflammatory response in the progression of AD.
机译:背景与目的:据报道,淀粉样蛋白(Aβ)肽可引发阿尔茨海默氏病(AD)人脑海马区的柔性炎症。本研究旨在探讨阿托伐他汀对AD模型海马炎症细胞因子产生的可能作用及其对行为能力的潜在影响。方法:首先建立脑室内注射Aβ1-42的AD大鼠模型。还进行了莫里斯水迷宫以确定AD模型中的空间学习和记忆能力。在注射Aβ后6小时和第7天,通过免疫组织化学染色测定了白介素(IL)-1β,IL-6和肿瘤坏死因子α的细胞内染色。结果:阿托伐他汀治疗的AD组的逃避潜伏期(5 mg / kg / d)在第3天(41±1.05秒vs 47±1.05秒,P <0.01)和第4天(34±1.25秒vs 43±1.01秒,P <0.01)显着低于AD组培训开始后。此外,用阿托伐他汀治疗的AD组的平均环穿次数明显高于AD组(2.9±0.5对2.4±0.9,P <0.05)。在阿托伐他汀治疗的AD组中,与AD组相比,受损神经细胞和神经胶质细胞的增殖也更少。十分重要的是,我们证明了阿托伐他汀治疗的AD组的IL-1β,IL-6和肿瘤坏死因子α明显低于AD组。结论:阿托伐他汀可能减轻神经细胞的损伤并改善学习通过抑制AD进展中的炎症反应而具有记忆和记忆能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号